Response to Zhang and Yang.
作者信息
Nielsen Torsten O, Leung Samuel C Y, McShane Lisa M, Dowsett Mitch, Hayes Daniel F
机构信息
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
出版信息
J Natl Cancer Inst. 2021 Nov 2;113(11):1597-1598. doi: 10.1093/jnci/djab094.
Abstract
摘要
相似文献
1
Response to Zhang and Yang.
J Natl Cancer Inst. 2021 Nov 2;113(11):1597-1598. doi: 10.1093/jnci/djab094.
2
3
[Research progress on the clinical value of Ki-67 in breast cancer and its cut-off definition].
Zhonghua Wai Ke Za Zhi. 2015 Aug 1;53(8):634-7.
4
[Correlation between immunohistochemical assessment of Ki-67 and clinicopathologic parameters in breast cancer].
Zhonghua Bing Li Xue Za Zhi. 2015 Sep;44(9):657-8.
5
The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis.
Future Oncol. 2017 Apr;13(9):843-857. doi: 10.2217/fon-2016-0420. Epub 2017 Jan 11.
6
[Interpretation of Ki-67 assessment update of International Ki-67 in Breast Cancer Working Group].
Zhonghua Bing Li Xue Za Zhi. 2021 Jul 8;50(7):704-709. doi: 10.3760/cma.j.cn112151-20210303-00179.
7
[Evaluation of Pre-Therapeutic Ki-67 as a Predictive Marker for Histological Response to Neoadjuvant Therapy in Breast Cancer].
Gan To Kagaku Ryoho. 2015 Nov;42(12):1491-3.
8
Ki-67 in breast cancer: .
Indian J Cancer. 2020 Jul-Sep;57(3):231-233. doi: 10.4103/ijc.IJC_565_19.
9
[Ki-67 labeling index as prognostic in breast cancer].
Nihon Rinsho. 2012 Sep;70 Suppl 7:180-4.
10
[Ki-67 expression and its effect on response to neo-adjuvant chemotherapy in invasive breast cancer].
Zhonghua Bing Li Xue Za Zhi. 2017 Dec 8;46(12):817-821. doi: 10.3760/cma.j.issn.0529-5807.2017.12.001.
引用本文的文献
1
Global scoring method of Ki67 immunohistochemistry in breast cancer demonstrates improved concordance using real-world multi-institutional data.
Breast Cancer Res. 2025 Sep 2;27(1):159. doi: 10.1186/s13058-025-02114-6.
2
The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations.
Cancers (Basel). 2023 Jan 28;15(3):808. doi: 10.3390/cancers15030808.
3
Validation of absolutely quantitated Ki67 and cyclinD1 protein levels for prognosis of Luminal-like breast cancer patients.
J Clin Lab Anal. 2022 Aug;36(8):e24601. doi: 10.1002/jcla.24601. Epub 2022 Jul 12.
4
Small non-coding RNA profiling in breast cancer: plasma U6 snRNA, miR-451a and miR-548b-5p as novel diagnostic and prognostic biomarkers.
Mol Biol Rep. 2022 Mar;49(3):1955-1971. doi: 10.1007/s11033-021-07010-8. Epub 2022 Jan 7.
5
Improving Prognosis of Surrogate Assay for Breast Cancer Patients by Absolute Quantitation of Ki67 Protein Levels Using Quantitative Dot Blot (QDB) Method.
Front Oncol. 2021 Sep 17;11:737781. doi: 10.3389/fonc.2021.737781. eCollection 2021.
本文引用的文献
1
External quality assessment (EQA) program for the immunohistochemical detection of ER, PR and Ki-67 in breast cancer: results of an interlaboratory reproducibility ring study in China.
BMC Cancer. 2019 Oct 22;19(1):978. doi: 10.1186/s12885-019-6210-3.
2
Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration.
NPJ Breast Cancer. 2016 May 18;2:16014. doi: 10.1038/npjbcancer.2016.14. eCollection 2016.
3
Quality assurance trials for Ki67 assessment in pathology.
Virchows Arch. 2017 Oct;471(4):501-508. doi: 10.1007/s00428-017-2142-y. Epub 2017 May 11.
Zotero 插件